Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Xinghua Pang, Zhaoliang Huang, Tingting Zhong, Peng Zhang, Zhongmin Maxwell Wang, Michelle Xia & Baiyong Li. (2023) Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. mAbs 15:1.
Read now
Read now
Junjie Gao, Dandan Yang, Haonan Xu, Kunpeng Yang, Jia Ma, Jun Xia & Xueshan Pan. (2022) ADAM metallopeptidase domain 12 overexpression correlates with prognosis and immune cell infiltration in clear cell renal cell carcinoma. Bioengineered 13:2, pages 2412-2429.
Read now
Read now
Maria Giuseppa Vitale, Cecilia Nasso, Marco Oltrecolli, Cinzia Baldessari, Martina Fanelli, Massimo Dominici & Roberto Sabbatini. (2021) Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma. Expert Review of Anticancer Therapy 21:11, pages 1183-1192.
Read now
Read now
Gerhard Hamilton. (2021) Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy. Expert Opinion on Biological Therapy 21:3, pages 311-322.
Read now
Read now
Articles from other publishers (35)
Rui Duarte, Filipa Trigo, Ivan Luz & Paulo Santos. (2023) Small-vessel vasculitis leading to severe acute kidney injury after ipilimumab: a case report. Melanoma Research.
Crossref
Crossref
Matteo Santoni, Alessandro Rizzo, Jakub Kucharz, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Elisa Tassinari, Fernando Sabino Marques Monteiro, Andrey Soares, Javier Molina-Cerrillo, Enrique Grande, Nicola Battelli & Francesco Massari. (2023) Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunology, Immunotherapy 72:6, pages 1365-1379.
Crossref
Crossref
Tsutomu Anraku, Hideki Hashidate, Asa Nakahara, Tomoyuki Imai & Yoshiaki Kawakami. (2023) Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy. BMC Urology 23:1.
Crossref
Crossref
Juan Pan, Tuxiong Huang, Zhenjun Deng & Chang Zou. (2023) Roles and therapeutic implications of m6A modification in cancer immunotherapy. Frontiers in Immunology 14.
Crossref
Crossref
Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Alessandro Rizzo, Matteo Santoni & Francesco Massari. (2022) Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nature Reviews Urology 20:3, pages 133-157.
Crossref
Crossref
Sai Krishnaraya Doppalapudi, Alain Kaldany, Benjamin Lichtbroun & Eric A. Singer. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
31
.
Juan WuYa-fei RenJun XieDong-sheng Li. (2022) Targeting CTLA-4 in Cancer: Biological Insights with a Focus on Renal Cell Carcinoma. annals of urologic oncology.
Crossref
Crossref
Mohammadsaleh Jahangir, Omid Yazdani, Mohammad Saeed Kahrizi, Sara Soltanzadeh, Hamidreza Javididashtbayaz, Azam Mivefroshan, Saba Ilkhani & Romina Esbati. (2022) Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. Cancer Cell International 22:1.
Crossref
Crossref
Alok K. Mishra, Amjad Ali, Shubham Dutta, Shahid Banday & Sunil K. Malonia. (2022) Emerging Trends in Immunotherapy for Cancer. Diseases 10:3, pages 60.
Crossref
Crossref
Belay Zeleke Sibuh, Rekha Gahtori, Noura Al-Dayan, Kumud Pant, Bahareh Farasati Far, Asrar Ahmad Malik, Ashish Kumar Gupta, Soumi Sadhu, Sushil Dohare & Piyush Kumar Gupta. (2022) Emerging trends in immunotoxin targeting cancer stem cells. Toxicology in Vitro 83, pages 105417.
Crossref
Crossref
Yuchen Wang, Hao Zhang, Chao Liu, Zeyu Wang, Wantao Wu, Nan Zhang, Longbo Zhang, Jason Hu, Peng Luo, Jian Zhang, Zaoqu Liu, Yun Peng, Zhixiong Liu, Lanhua Tang & Quan Cheng. (2022) Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Natalia Miheecheva, Ekaterina Postovalova, Yang Lyu, Akshaya Ramachandran, Alexander Bagaev, Viktor Svekolkin, Ilia Galkin, Vladimir Zyrin, Vladislav Maximov, Yaroslav Lozinsky, Sergey Isaev, Pavel Ovcharov, Diana Shamsutdinova, Emily H. Cheng, Krystle Nomie, Jessica H. Brown, Maria Tsiper, Ravshan Ataullakhanov, Nathan Fowler & James J. Hsieh. (2022) Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity. Cell Reports 40:7, pages 111180.
Crossref
Crossref
A Nayak, J Piedad, Y Wagh, P Nathan, A Sharma, B Pullar, D Hanbury & J Adshead. (2022) A comparison of cytoreductive and non-cytoreductive management strategies for nephron-sparing approaches to tumours in solitary kidneys. The Annals of The Royal College of Surgeons of England 104:7, pages 548-552.
Crossref
Crossref
Jiao Xue, Yining Zhu, Shuting Bai, Chunting He, Guangsheng Du, Yuandong Zhang, Yao Zhong, Wenfei Chen, Hairui Wang & Xun Sun. (2022) Nanoparticles with rough surface improve the therapeutic effect of photothermal immunotherapy against melanoma. Acta Pharmaceutica Sinica B 12:6, pages 2934-2949.
Crossref
Crossref
Irina Palacín-Aliana, Josefa Carrión-Navarro, Ángel Ayuso-Sacido & Noemí García-Romero. 2022. Translational Autoimmunity. Translational Autoimmunity
51
71
.
Iago Dillion Lima CavalcantiIago Dillion Lima Cavalcanti. 2022. Chemotherapy Protocols and Infusion Sequence. Chemotherapy Protocols and Infusion Sequence
201
231
.
Yanhua Mou, Jinchun Wu, Yao Zhang, Omar Abdihamid, Chaojun Duan & Bin Li. (2021) Low expression of ferritinophagy-related NCOA4 gene in relation to unfavorable outcome and defective immune cells infiltration in clear cell renal carcinoma. BMC Cancer 21:1.
Crossref
Crossref
Alessandro Rizzo, Veronica Mollica, Matteo Santoni & Francesco Massari. (2021) Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution. Journal of Clinical Medicine 10:22, pages 5246.
Crossref
Crossref
Sai Krishnaraya Doppalapudi, Zev R. Leopold, Akshay Thaper, Alain Kaldany, Kevin Chua, Hiren V. Patel, Arnav Srivastava & Eric A. Singer. (2021) Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC. Cancers 13:16, pages 4140.
Crossref
Crossref
Long Ma, Gang Jin, Keying Yao, Yi Yang, Ruitong Chang, Wenhao Wang, Jiawei Liu & Zijiang Zhu. (2021) Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Magdalena Rausch, Adriano Rutz, Pierre-Marie Allard, Céline Delucinge-Vivier, Mylène Docquier, Olivier Dormond, Paul J. Dyson, Jean-Luc Wolfender & Patrycja Nowak-Sliwinska. (2021) Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma. Cancers 13:16, pages 3978.
Crossref
Crossref
Magdalena Rausch, Léa Blanc, Olga De Souza Silva, Olivier Dormond, Arjan W. Griffioen & Patrycja Nowak-Sliwinska. (2021) Characterization of Renal Cell Carcinoma Heterotypic 3D Co-Cultures with Immune Cell Subsets. Cancers 13:11, pages 2551.
Crossref
Crossref
R. Kleef, R. Nagy, A. Baierl, V. Bacher, H. Bojar, D. L. McKee, R. Moss, N. H. Thoennissen, M. Szász & T. Bakacs. (2020) Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution. Cancer Immunology, Immunotherapy 70:5, pages 1393-1403.
Crossref
Crossref
Ana Lúcia Silva, Pedro Abreu-Mendes, Diana Martins & Fernando Mendes. (2021) The Impact of Immune Checkpoint-Inhibitors Therapy in Urinary Bladder Cancer. Onco 1:1, pages 3-22.
Crossref
Crossref
Maryanne M. Gonzales Carazas, Joseph A. Pinto & Fanny L. Casado. (2021) Biological bases of cancer immunotherapy. Expert Reviews in Molecular Medicine 23.
Crossref
Crossref
Toshihiko Masago, Susumu Kobayakawa, Yuu Ohtani, Kenjirou Taniguchi, Takuji Naka, Naoto Kuroda, Chihiro Takahashi, Tadahiro Isoyama & Takehiro Sejima. (2020) Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion in the elderly: case report and literature review. International Cancer Conference Journal 9:4, pages 182-186.
Crossref
Crossref
Yuxiao Song, Yang Fu, Qi Xie, Bo Zhu, Jun Wang & Bicheng Zhang. (2020) Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Frontiers in Immunology 11.
Crossref
Crossref
Kevin Dzobo, Dimakatso Alice Senthebane, Chelene Ganz, Nicholas Ekow Thomford, Ambroise Wonkam & Collet Dandara. (2020) Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review. Cells 9:8, pages 1896.
Crossref
Crossref
Koichi Ando, Yasunari Kishino, Tetsuya Homma, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi & Hironori Sagara. (2020) Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Cancers 12:7, pages 1905.
Crossref
Crossref
Hui You, Yi-Zhong Zhang, Huan-Ling Lai, Dan Li, Yu-Quan Liu, Run-Ze Li, Imran Khan, Wendy Wen-Lun Hsiao, Fu-Gang Duan, Xing-Xing Fan, Xiao-Jun Yao, Ya-Bing Cao, Qi-Biao Wu, Elaine Lai-Han Leung & Mei-Fang Wang. (2020) Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology 146:6, pages 1441-1450.
Crossref
Crossref
Yu-Chen Chuang, Jen-Chih Tseng, Li-Rung Huang, Chun-Ming Huang, Chi-Ying F. Huang & Tsung-Hsien Chuang. (2020) Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade. Frontiers in Immunology 11.
Crossref
Crossref
Marie-France Savard, J. Connor Wells, Jeffrey Graham, Shaan Dudani, John A. Steinharter, Bradley A. McGregor, Frede Donskov, Georg A. Bjarnason, Ulka N. Vaishampayan, Aaron R. Hansen, Marco A.J. Iafolla, Giovanni Zanotti, Lynn Huynh, Rose Chang, Mei S. Duh & Daniel Y.C. Heng. (2020) Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. The Oncologist 25:5, pages 422-430.
Crossref
Crossref
Peng Zhang, Xinxin Xiong, Christian Rolfo, Xuexiang Du, Yan Zhang, Han Yang, Alessandro Russo, Martin Devenport, Penghui Zhou, Yang Liu & Pan Zheng. (2020) Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies. Cancers 12:2, pages 284.
Crossref
Crossref
George Mattheolabakis & Constantinos M. Mikelis. (2019) Nanoparticle Delivery and Tumor Vascular Normalization: The Chicken or The Egg?. Frontiers in Oncology 9.
Crossref
Crossref
Javier C. Angulo & Oleg Shapiro. (2019) The Changing Therapeutic Landscape of Metastatic Renal Cancer. Cancers 11:9, pages 1227.
Crossref
Crossref